6533b853fe1ef96bd12abfd4

RESEARCH PRODUCT

A nonrandomized, phase IV trial of FOLFIRI and cetuximab in first-line treatment of metastatic colorectal cancer receiving a predefined skin care and skin prophylaxis aiming to prevent a skin rash.

Markus MoehlerKlaus Maria JostenMichael NeiseCarmen DhensawHolger HebartClaudia LangM. A. WoernsJochen RudiMeinolf KarthausThomas GeerJan WiereckyPeter R. GallePeter EhscheidtMichael HeikeThomas GoehlerThomas FlohrGerrit DingeldeinCarl C. SchimanskiAlexander Schmittel

subject

OncologySkin careCancer Researchmedicine.medical_specialtyCetuximabColorectal cancerbusiness.industrymedicine.diseaseRashPhase IV TrialSurgeryFirst line treatmentOncologyInternal medicinemedicineFOLFIRIOverall survivalmedicine.symptombusinessmedicine.drug

description

e20724 Background: Anti-EGFR empowered chemotherapeutic regimens resulted in increased overall survival (OS) and response rates (RR). Anti-EGFR induced skin rash occurs in ~ 70% patients, and ~18% ...

https://doi.org/10.1200/jco.2014.32.15_suppl.e20724